17.07.2013 Views

View Annual Report - Jules Stein Eye Institute

View Annual Report - Jules Stein Eye Institute

View Annual Report - Jules Stein Eye Institute

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

Alejandra Young, PhD<br />

Debora B. Farber, PhD, DPhhc (Mentor)<br />

Interactions of the Melanosomal G-Protein-Coupled Receptor<br />

OA1 and Gai Proteins in the Retinal Pigment Epithelium<br />

Vision of Children Foundation<br />

Duration: 6/1/10–5/31/12 $222,757<br />

<strong>Eye</strong>STAR Graduate Student Grants<br />

Diana Katsman, MD, and Debora B. Farber, PhD, DPhhc<br />

Activation of Retinal Regenerative Potential by<br />

Embryonic Stem Cell-Derived Microvesicles<br />

Hope for Vision<br />

Duration: 1/15/10–1/14/12 $150,000<br />

Clinical Trials<br />

Lynn Gordon, M.D., Ph.D.<br />

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Weight-Reduction<br />

and/or Low Sodium Diet Plus Acetazolamide vs. Diet Plus Placebo I<br />

St. Luke’s College of Health Sciences<br />

Duration: 4/8/2010–1/31/12 $137,091<br />

A Phase 1 Open Label, Dose Escalation Trial of QPI-1007 Delivered by a Single Intravitreal<br />

Injection to Patients with Optic Nerve Atrophy<br />

Quark Pharmaceuticals<br />

Duration: 3/17/10–3/16/15 $248,024<br />

Case-Crossover Study of PDE5 Inhibitor Exposure as a Potential “Trigger Factor”<br />

for Acute NAION<br />

ICON Clinical Research, Inc.<br />

Duration: 6/24/09–11/15/12 $43,580<br />

Jean-Pierre Hubschman, MD<br />

A Phase III, Multicenter, Randomized, Double-Masked Study Comparing<br />

the Efficacy and Safety of 0.5 mg and 2.0 mg of Ranibizumab<br />

Genentech<br />

Duration: 10/13/09–3/1/13 $845,625<br />

Steven D. Schwartz, MD<br />

Research with Retinal Cells Derived from Stem Cells for<br />

Stargardt Macular Dystrophy<br />

Advanced Cell Technology<br />

Duration: 3/23/11–3/22/13 $762,184<br />

Research with Retinal Cells Derived from Stem Cells for<br />

Age-Related Macular Degeneration<br />

Advanced Cell Technology<br />

Duration: 4/5/11–4/5/13 $835,693<br />

Applicator System in the Treatment of Patients with Diabetic Macular Edema<br />

Allergan Sales, LLC<br />

Duration: 8/25/05–12/31/13 $1,604,947<br />

Total awards for NIH, Clinical, and PI-Initiated Research include indirect cost.<br />

104 Appendices | Research Contracts and Grants

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!